Recruiting Type 2 Diabetes Studies in Phoenix
A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. ...
Pentoxifylline in Diabetic Kidney Disease
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys f...
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN)....
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic ma...
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibi...
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1...
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who...
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a sta...
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes....
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study. The purpose of this study is to find ou...
About Type 2 Diabetes Clinical Trials in Phoenix
Type 2 diabetes is a chronic metabolic condition affecting over 37 million Americans, characterized by insulin resistance and progressive loss of beta-cell function. While metformin remains the first-line treatment, the treatment landscape has expanded dramatically with GLP-1 receptor agonists (semaglutide, tirzepatide), SGLT2 inhibitors (empagliflozin, dapagliflozin), and dual GIP/GLP-1 agonists showing both glycemic and cardiovascular benefits. Clinical trials are now exploring triple-hormone agonists, oral GLP-1 formulations, islet cell regeneration therapies, and precision medicine approaches that tailor treatment to individual metabolic profiles. Patients with uncontrolled HbA1c on current medications, those with diabetic complications, or newly diagnosed patients may qualify for enrollment.
There are currently 10 type 2 diabetes clinical trials recruiting participants in Phoenix, ARIZONA. These studies are seeking a combined 18,544 participants. Research is being sponsored by Boehringer Ingelheim, VA Office of Research and Development, Vertex Pharmaceuticals Incorporated and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Type 2 Diabetes Clinical Trials in Phoenix — FAQ
Are there type 2 diabetes clinical trials in Phoenix?
Yes, there are 10 type 2 diabetes clinical trials currently recruiting in Phoenix, ARIZONA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Phoenix?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.
Are clinical trials in Phoenix free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.
What type 2 diabetes treatments are being tested?
The 10 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for type 2 diabetes.
Data updated March 2, 2026 from ClinicalTrials.gov